Tina Catela Ivkovic
Overview
Explore the profile of Tina Catela Ivkovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pokorna P, Palova H, Adamcova S, Jugas R, Al Tukmachi D, Kyr M, et al.
Lab Invest
. 2024 Oct;
104(12):102161.
PMID: 39442669
Despite significant improvement in the survival of pediatric patients with cancer, treatment outcomes for high-risk, relapsed, and refractory cancers remain unsatisfactory. Moreover, prolonged survival is frequently associated with long-term adverse...
2.
Budinska E, Carnogurska M, Catela Ivkovic T, Machackova T, Boudna M, Pifkova L, et al.
Front Oncol
. 2024 May;
14:1367231.
PMID: 38706608
Stage II colon cancer (CC) encompasses a heterogeneous group of patients with diverse survival experiences: 87% to 58% 5-year relative survival rates for stages IIA and IIC, respectively. While stage...
3.
Boudna M, Machackova T, Vychytilova-Faltejskova P, Trachtova K, Bartosova R, Catela Ivkovic T, et al.
Clin Exp Med
. 2024 Apr;
24(1):67.
PMID: 38568288
Colorectal cancer (CRC) is the second most prevalent cancer type worldwide, which highlights the urgent need for non-invasive biomarkers for its early detection and improved prognosis. We aimed to investigate...
4.
Budinska E, Hrivnakova M, Catela Ivkovic T, Madrzyk M, Nenutil R, Bencsikova B, et al.
Elife
. 2023 Nov;
12.
PMID: 37956043
Heterogeneity of colorectal carcinoma (CRC) represents a major hurdle towards personalized medicine. Efforts based on whole tumor profiling demonstrated that the CRC molecular subtypes were associated with specific tumor morphological...
5.
Catela Ivkovic T, Cornella H, Voss G, Ku A, Persson M, Rigo R, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568709
Distant metastasis is the major cause of cancer-related deaths in men with prostate cancer (PCa). An in vivo functional screen was used to identify microRNAs (miRNAs) regulating metastatic dissemination of...
6.
Vychytilova-Faltejskova P, Vilmanova S, Pifkova L, Catela Ivkovic T, Mdrzyk M, Jugas R, et al.
Clin Chem Lab Med
. 2023 Jul;
62(1):157-167.
PMID: 37505924
Objectives: Small extracellular vesicles (EVs) contain various signaling molecules, thus playing a crucial role in cell-to-cell communication and emerging as a promising source of biomarkers. However, the lack of standardized...
7.
Marinovic S, Skrtic A, Catela Ivkovic T, Poljak M, Kapitanovic S
Hum Cell
. 2021 Jul;
34(5):1455-1465.
PMID: 34235620
Colorectal carcinoma (CRC) results from the accumulation of genetic mutations and alterations in signaling pathways. KRAS is mutated in 40% of CRC cases and is involved in increased tumor cells...
8.
Chen B, Dragomir M, Fabris L, Bayraktar R, Knutsen E, Liu X, et al.
Gastroenterology
. 2020 Aug;
159(6):2146-2162.e33.
PMID: 32805281
Background & Aims: Chromosomal instability (CIN) is a carcinogenesis event that promotes metastasis and resistance to therapy by unclear mechanisms. Expression of the colon cancer-associated transcript 2 gene (CCAT2), which...
9.
Pichler M, Rodriguez-Aguayo C, Nam S, Dragomir M, Bayraktar R, Anfossi S, et al.
Gut
. 2020 Jan;
69(10):1818-1831.
PMID: 31988194
Objective: To investigate the function of a novel primate-specific long non-coding RNA (lncRNA), named FLANC, based on its genomic location (co-localised with a pyknon motif), and to characterise its potential...
10.
Noskova H, Kyr M, Pal K, Merta T, Mudry P, Polaskova K, et al.
Cancers (Basel)
. 2020 Jan;
12(1).
PMID: 31963488
Background: Tumor mutational burden (TMB) is an emerging genomic biomarker in cancer that has been associated with improved response to immune checkpoint inhibitors (ICIs) in adult cancers. It was described...